Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05753449 · ClinicalTrials.gov registry record · NA
Burst-Type Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
A NA study, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT05753449: Clinical Trial NA study, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
NCT05753449 is a NA study that was terminated before completion, run by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05753449, a NA study, was terminated before completion, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute).
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a study to evaluate Deep brain stimulation (DBS) burst-type electrical stimulation programming verses standard DBS programming. Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered. Burst type DBS may improve the efficacy and durability of DBS pulse generator.
Primary Outcome
This outcome is the Unified Parkinson's Disease Rating Scale (UPDRS) v-III Motor Examination Score in the "Medication Off" state, after the first treatment (administered for 30 minutes) and after the second treatment (administered for 30 minutes). For example, the first treatment for patients in the arm "Baseline Programming First, Then Experimental Burst-type Programming" was baseline (or standard of care) DBS programming, and the second treatment was experimental Burst-style programming. Each
Interventions
- DEVICE Baseline (or standard of care) DBS programming
- DEVICE Burst-type DBS electrical stimulation programming
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2024-02-21 |
| Phase | NA |
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)34 total trials
Why NCT05753449 stopped before completion
NCT05753449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Baseline (or standard of care) DBS programming is the first listed.
NCT05753449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05753449 about?
NCT05753449 is a clinical study titled "Burst-Type Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease". This is a study to evaluate Deep brain stimulation (DBS) burst-type electrical stimulation programming verses standard DBS programming. Burst-type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered. Bur...
What is the current status of trial NCT05753449?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2022-08-24. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT05753449?
The interventions under investigation include: Baseline (or standard of care) DBS programming (DEVICE), Burst-type DBS electrical stimulation programming (DEVICE).
Who is sponsoring clinical trial NCT05753449?
This trial is sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05753449's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI